Tags

Type your tag names separated by a space and hit enter

Early prediction of molecular remission by monitoring BCR-ABL transcript levels in patients achieving a complete cytogenetic response after imatinib therapy for posttransplantation chronic myelogenous leukemia relapse.
Biol Blood Marrow Transplant 2004; 10(10):718-25BB

Abstract

Imatinib induces a high complete cytogenetic response (CCR) rate in relapsed chronic myelogenous leukemia. By analyzing minimal residual disease (MRD) under the levels of CCR, we tried to assess the molecular response after imatinib therapy. By using real-time quantitative reverse transcriptase-polymerase chain reaction (Q-RT-PCR), MRD was evaluated in 23 patients (3 in cytogenetic relapse, 6 in chronic phase, 9 in accelerated phase, and 5 in blast crisis) who were treated with standard-dose imatinib for relapsed chronic myelogenous leukemia after allogeneic stem cell transplantation. With a median therapy time of 399 days (range, 35-817 days), 19 (83%) patients achieved a CCR. Meanwhile, 11 (58%) of them achieved a molecular remission (MR), which was associated with improved survival. The Q-RT-PCR data were compared according to the best response (MR, n = 11; CCR, n = 8) in the patients achieving a CCR. The BCR-ABL/ABL ratios were similar in 2 groups at 3 months but were significantly different at 6 months (median, 0.0000012 for MR and 0.00022 for CCR; P =.003). The probability of a subsequent MR was significantly higher in patients with a lower BCR-ABL/ABL ratio at 6 months (100% for <0.0001 versus 33% for >/=0.0001; P =.006) or a greater reduction in the level between 3 and 6 months (log-reduction >/=1.0;, 100%; <1.0, 17%; P =.003). Q-RT-PCR is a reliable method for monitoring MRD: the early trends in the BCR-ABL/ABL ratio may be clinically useful in discriminating patients who will achieve an MR from those who will remain in CCR.

Authors+Show Affiliations

Catholic Hematopoietic Stem Cell Transplantation Center, Catholic University of Korea, Seoul, Korea.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15389438

Citation

Kim, Yoo-Jin, et al. "Early Prediction of Molecular Remission By Monitoring BCR-ABL Transcript Levels in Patients Achieving a Complete Cytogenetic Response After Imatinib Therapy for Posttransplantation Chronic Myelogenous Leukemia Relapse." Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation, vol. 10, no. 10, 2004, pp. 718-25.
Kim YJ, Kim DW, Lee S, et al. Early prediction of molecular remission by monitoring BCR-ABL transcript levels in patients achieving a complete cytogenetic response after imatinib therapy for posttransplantation chronic myelogenous leukemia relapse. Biol Blood Marrow Transplant. 2004;10(10):718-25.
Kim, Y. J., Kim, D. W., Lee, S., Min, C. K., Goh, H. G., Kim, S. H., ... Kim, C. C. (2004). Early prediction of molecular remission by monitoring BCR-ABL transcript levels in patients achieving a complete cytogenetic response after imatinib therapy for posttransplantation chronic myelogenous leukemia relapse. Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation, 10(10), pp. 718-25.
Kim YJ, et al. Early Prediction of Molecular Remission By Monitoring BCR-ABL Transcript Levels in Patients Achieving a Complete Cytogenetic Response After Imatinib Therapy for Posttransplantation Chronic Myelogenous Leukemia Relapse. Biol Blood Marrow Transplant. 2004;10(10):718-25. PubMed PMID: 15389438.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Early prediction of molecular remission by monitoring BCR-ABL transcript levels in patients achieving a complete cytogenetic response after imatinib therapy for posttransplantation chronic myelogenous leukemia relapse. AU - Kim,Yoo-Jin, AU - Kim,Dong-Wook, AU - Lee,Seok, AU - Min,Chang-Ki, AU - Goh,Hyun-Gyung, AU - Kim,Su-Hyun, AU - Lee,Ji-Young, AU - Kim,Yoo-Li, AU - Kim,Hee-Je, AU - Kim,Hyeoung-Jun, AU - Lee,Jong-Wook, AU - Kim,Tai-Gyu, AU - Min,Woo-Sung, AU - Kim,Chun-Choo, PY - 2004/9/25/pubmed PY - 2005/3/16/medline PY - 2004/9/25/entrez SP - 718 EP - 25 JF - Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation JO - Biol. Blood Marrow Transplant. VL - 10 IS - 10 N2 - Imatinib induces a high complete cytogenetic response (CCR) rate in relapsed chronic myelogenous leukemia. By analyzing minimal residual disease (MRD) under the levels of CCR, we tried to assess the molecular response after imatinib therapy. By using real-time quantitative reverse transcriptase-polymerase chain reaction (Q-RT-PCR), MRD was evaluated in 23 patients (3 in cytogenetic relapse, 6 in chronic phase, 9 in accelerated phase, and 5 in blast crisis) who were treated with standard-dose imatinib for relapsed chronic myelogenous leukemia after allogeneic stem cell transplantation. With a median therapy time of 399 days (range, 35-817 days), 19 (83%) patients achieved a CCR. Meanwhile, 11 (58%) of them achieved a molecular remission (MR), which was associated with improved survival. The Q-RT-PCR data were compared according to the best response (MR, n = 11; CCR, n = 8) in the patients achieving a CCR. The BCR-ABL/ABL ratios were similar in 2 groups at 3 months but were significantly different at 6 months (median, 0.0000012 for MR and 0.00022 for CCR; P =.003). The probability of a subsequent MR was significantly higher in patients with a lower BCR-ABL/ABL ratio at 6 months (100% for <0.0001 versus 33% for >/=0.0001; P =.006) or a greater reduction in the level between 3 and 6 months (log-reduction >/=1.0;, 100%; <1.0, 17%; P =.003). Q-RT-PCR is a reliable method for monitoring MRD: the early trends in the BCR-ABL/ABL ratio may be clinically useful in discriminating patients who will achieve an MR from those who will remain in CCR. SN - 1083-8791 UR - https://www.unboundmedicine.com/medline/citation/15389438/Early_prediction_of_molecular_remission_by_monitoring_BCR_ABL_transcript_levels_in_patients_achieving_a_complete_cytogenetic_response_after_imatinib_therapy_for_posttransplantation_chronic_myelogenous_leukemia_relapse_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1083879104003726 DB - PRIME DP - Unbound Medicine ER -